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INTRODUCTION
In Korea, breast cancer ranks the second most common
cancer after stomach cancer in women, and its rate is gradu-
ally increasing (1). Despite having similar histological find-
ings, breast cancer cases have distinctly different biological
behaviors, so that it is difficult to evaluate the prognosis of
breast cancer and to predict its response to treatment and
the likelihood of recurrence. Traditionally, prognostic factors
of breast cancer include axillary nodal status, tumor size, his-
tological grade, pathologic subtype, cancer cell proliferation,
and hormonal receptor status (2). The biological markers,
for example c-erbB2, p53, Bcl-2, Ki-67 labeling index etc.,
have been intensively investigated as new prognostic or pre-
dictive markers, and are currently applied in the management
of breast cancer patients in many hospitals. 
Apoptosis is the process of active cell death that is observed
in the generation of multinuclear creatures and the preserva-
tion of individuals (3). Recently, a great deal of interest has
been devoted to the role of apoptosis in tumorigenesis. Bcl-
2 was first identified as repressor of apoptosis and Bcl-2-relat-
ed genes are involved in the regulation of apoptosis that is
implicated in a variety of cellular activities, including the
transformation of a normal cell into a cancer cell (4). At pre-
sent, the reported Bcl-2-related genes are Bax, Bcl-x, mcl-1,
A1, Bak, ced-9, Bfl-1, and BRAG-1. Among these, the Bfl-
1 gene, which is isolated from human fetal liver, is a mem-
ber of the Bcl-2 gene family and was only recently described,
inhibits p53-induced apoptosis and exhibits a potent coop-
erative transforming activity (5, 6). Bfl-1 was also shown to
be induced by inflammatory cytokines, TNF- or IL-1 ,
suggesting that it may play a protective role during inflam-
mation (8). It has been reported that over-expression of the
Bfl-1 homologous genes, Bcl-2, Bax, and Bcl-x has a relation-
ship with prognosis of breast cancer, but there has been no
reports on the prognostic relevance of the Bfl-1 gene in lit-
erature.
The purpose of the present study was to compare the
expression of the Bfl-1 gene by reverse transcriptase-poly-
merase chain reaction (RT-PCR) analysis with other prog-
nostic factors, such as the status of hormonal receptors, p53,
c-erbB2, Bcl-2, and tumor infiltrating lymphocytes (TIL)
and the most important clinicopathologic parameters. 
PATIENTS AND METHODS
The study was performed on 30 breast cancer tissue sam-
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Bfl-1 Gene Expression in Breast Cancer
: Its Relationship with other Prognostic Factors 
The Bfl-1 gene, which was isolated from human fetal liver and only recently de-
scribed, is a member of the Bcl-2 gene family. Reverse transcriptase-polymerase
chain reaction was performed on RNA drawn from 30 breast cancer tissues to com-
pare the expression of the Bfl-1 gene with other prognostic factors. The median
relative ratio was 3.0 (range, 0.12-26.83) and the Bfl-1 gene expression rate was
36.7% (11/30). There was no statistically significant relationship between the clini-
copathologic parameters of patients and the expression value of Bfl-1 gene. The
level of Bfl-1 gene expression was higher in more advanced breast cancers than
in early cancers. There was no significant relationship between the expression val-
ues and currently acknowledged prognostic factors, but a higher expression pattern
was noticed in the groups of positive hormone receptors and negative p53 and neg-
ative c-erbB2, albeit statistically not significant. It seems that the increased expres-
sion of the Bfl-1 gene serves as a contributory factor in breast cancer, in the same
way that another group of genes, the Bcl-2 family, contributes to apoptosis. 
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ples. All the patients were enrolled at the Department of
Surgery of Asan Medical Center in Korea. None of the breast
cancer patients received preoperative radiation treatment or
chemotherapy. Patients were treated by mastectomy or breast-
conserving surgery. The median age of the patients was 47.5
yr (range, 32-83 yr). Nineteen (63.3%) patients were pre-
menopausal and 11 (36.7%) were postmenopausal. During
surgery, after the tumor had been cut in half, about 1 g of
tumor tissue was frozen in liquid nitrogen immediately after
surgical resection and stored at -80℃until being processed.
The rest of the tissue was processed for histopathological
examination, and immunohistochemical analysis was per-
formed for the expression of the estrogen and progesterone
receptors, p53, and c-erbB2, Bcl-2 using the antibody for
individual proteins by routine ABC method. All the patients
were staged according to the AJCC/UICC classification sys-
tem, and each tumor was graded as a histologically by the
Bloom and Richardson grading system. 
Semiquantitative RT-PCR analysis
Total RNA was isolated from tissue samples using Tri-
reagent (Sigma, T9424) after removal of contaminating chro-
mosomal DNA with DNAse I treatment, and then was
reverse transcribed by the Moloney murine leukemia virus
reverse transcriptase (Gibco BRL, Gainthersberg, MD, U.S.A.)
and oligo dT primers (Promega, Medison, WI, U.S.A.) to
synthesize the first-strand complementary DNA (cDNA).
Three microliters of cDNA were then amplified by poly-
merase chain reaction (PCR). The  -globin gene served as
internal control. The primer used were: Bfl-1 upstream
primer: 5、 -AGCTCAAGACTTTGCTCTCCACC-3、 ; Bfl-1
downstream primer: 5、 -TGGAGTGTCCTTTCTGGTGA-
CATTAAGG-3、 ; -globin upstream primer: 5、 -GACA-
CAACGTTCATAG 3、 ; -globin downstream primer: 5、 -
AGGGTAGACACCAGCAGC-3、 . PCR was performed in
a 30  L reaction volume with the following parameters: 94
℃ for 5 min; 94℃ for 45 sec; 60℃ for 45 sec; 72℃ for 30
sec for 28 cycles; and 72℃ for 10 min. PCR products were
electrophoresed on 2% agarose gels and visualized by stain-
ing with ethidium bromide (9). The gel was scanned, and
the band intensity was measured by a computerized densito-
metric analysis device. We calculated the ratio of the inten-
sity of the Bfl-1 bands to the intensity of the  -globin bands.
We considered any ratio greater than 5 to indicate expres-
sion of the Bfl-1 gene. 
Measurement of Tumor Infiltrating Lymphocytes (TIL)
The 5- m thick sections of the formalin-fixed, paraffin-
embedded blocks were used for hematoxylin-eosin stains.
Using a microscope, a total of three areas of tumor with infil-
tration by TILs were selected for the counting of TILs in the
following order: (a) TIL1, the area of the maximal number of
TILs; (b) TIL2, the area of tumor with a median number of
TILs in each case; and (c) TIL3, the area with the lowest num-
ber of TILs as judged by examination at low-power magni-
fication (×100). For the counting of TILs, a high-powered
magnification (×200) image was captured by Image Pro Plus
(version 4.0, Media Cybernetics), and printed out on a devel-
oping paper. The TILs in the entire image were counted using
grids, and we calculated the mean number of the  three areas.
The infiltration of TILs was divided into 3 groups: patients
with a low number of TIL infiltration (<100 cells/highpow-
er field), a moderate number (100< and <300), and a high
number (>300).  
Statistical Analysis
The Chi-squared test, Fisher’s exact test, the Mann-Whit-
ney nonparametric test, or Pearson’s correlation test was used
to analyze the expression of the Bfl-1 levels according to the
clinicopathological characteristics, other prognostic factors
and TIL, as appropriate. Those with p<0.05 were considered
significant. 
RESULTS 
The median relative ratio was 3.0 (range, 0.12-26.83) and
the Bfl-1 gene expression rate was 36.7% (11/30) (Fig. 1).
No statistically significant relationship was found between
the clinicopathologic parameters of patients: menopausal sta-
tus, tumor size, axillary nodal status, stage, histologic grade,
lympho-vascular invasion of tumor, and the relative ratio
numerical values of gene expression. However, the median
value was 2.14 (range, 0.83-3.34) in the group with stage 0
and stage I, but the value was 4.09 (range; 0.12-26.83) in the
group with stage II or over. Therefore, a lower level of expres-
sion of the Bfl-1 gene was shown in cases of the early stage
of breast cancer. Compared with other cases, higher intensi-
ty of expression was displayed in cases with larger tumors and
in those with metastasis to axillay lymph nodes showed high-
Fig. 1. RT-PCR analysis of Bfl-1 mRNA in breast cancer tissues.
lanes 1-8, patient number: lane 9, positive control (B-cell lympho-
ma): lane 10, negative control (liver tissue).
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er intensity of expression (1.86 versus 4.06, 2.61 versus 4.57).
These observations showed that the Bfl-1 gene was highly
expressed in more advanced breast cancers than in early can-
cers. There was no significant relationship between expression
values and currently acknowledged prognostic factors, that
is estrogen and progesterone receptors, p53, and c-erbB2,
but a higher expression pattern was noticed in the groups of
positive hormone receptors and negative p53 and negative
c-erbB2, albeit without statistical significance. Regarding
the gene expression rate, none of the group of 7 patients with
tumors smaller than 2 cm showed expression, while 52.2%
(11/23) of those in the group with tumors larger than 2 cm
(p=0.029) did. This trend could also be applied to patients
with breast cancer of stage 0 or I and of stage II: the former
group was markedly different from the latter (p=0.02). In the
group with only positive estrogen receptor among other prog-
nostic factors, 9 out of 16 cases showed expression (56.3%)
compared to 14.3% (2/14) of the negative cases (p=0.017)
(Table 1). In the group with positive expression of the Bcl-2
No. of  Ratio to internal control * Expression (%)
patients Median Range Present  (n=11)
Menopausal status
premenopause 19 3.20 0.5-26.83 7 (26.8)
postmenopause 11 2.79 0.12-26.76 4 (26.4)
Tumor size
< 2 cm 7 1.86  1.50-3.34 0 (0)
�
> 2 cm  23 4.09 0.12-26.83                             11 (52.2)
Stage
0, I 7 2.14 0.83-3.34 0 (0)
�
II, III 23 4.09 0.12-26.83                             11 (52.2)
Node
negative 14 2.61 0.50-6.56 3 (21.4)
positive 16 4.57 1.11-26.83 8 (50.0)
Histologic grade
1, 2 13 2.64  0.12-26.76 6 (46.2)
3 16 3.27 0.50-26.83 5 (31.2)
Lympho-vascular tumor emboli
No 20 2.99 0.12-26.76 6 (30.0)
Yes 9 2.64 0.50-12.63 4 (44.4)
Extranodal extension
negative 16 2.61 0.12-26.76 4 (25.0)
positive 13 5.20 1.25-26.83 7 (53.8)
Estrogen receptor
negative 14 2.54 0.50-26.83 2 (14.3)
�
positive 16 5.35 0.12-26.76 9  (56.2)
Progestrerone receptor
negative 14 2.72 0.50-26.83 3 (21.4)
positive 16 4.72 0.12-26.76 8 (50.0)
P53
negative 19 3.93 0.12-26.76 8 (42.1)
positive 11 2.79 1.07-2.92 3 (27.3)
c-erbB2
negative 13 4.09 1.34-26.83 6 (46.2)
positive 17 2.44 0.12-11.67 5 (29.4)
*: The difference between subgroup, as determined by the Mann-Whitney U test, was not significant (p>0.05); 
� : Statistically significant (p<0.05).
Table 1. Clinical data of patients and result of Bfl-1 gene expression
Fig. 2. Box and whiskers plots showing the distribution of Bfl-1
values, expressed as relative ratio in the category of Bcl-2 pro-
tein expression-the median values are indicated as a line across
each box.
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protein, the expression value of the Bfl-1 gene ranged between
0.83 and 26.76 (median value, 5.93), and the gene expression
rate was 64.3% (9/14). On the other hand, in the group with
negative Bcl-2 expression, the value ranged from 0.12 to
26.83 (median value, 2.29) and 12.5% (2/16). This obser-
vation suggests that there would be a significant relationship
between the two genes (p<0.04) (Fig. 2). Infiltration of TILs
was present in the tumor stroma in all examined cases. The
distribution of TILs was uneven with the heaviest infiltration
at the periphery of the tumor in most cases. The TIL infil-
tration ranged from 0 cells per high-power field to 530 cells
per high-power field in cancerous tissue, with a mean num-
ber ranging between 1 and 502 (total mean number, 150.4).
For the grade of TIL density, the rates of the low, moderate,
high density groups were 46.7%, 30.0%, and 23.3%, retro-
spectively. However, a correlation between the density dif-
ference of tumor infiltrating lymphocytes and the expression
of the Bfl-1 gene was not found. 
DISCUSSION
Despite the gradual increase in the incidence of breast can-
cer worldwide, there has been only substantial improvement
in the management of breast cancer that has contributed to
the substantial fall in its mortality since 1990. A major con-
tributor to this decrease is clearly the widespread application
of hormonal and adjuvant chemotherapy after surgery. How-
ever it is essential to understand the characteristics of breast
cancer, including the carcinogenic process itself and its patho-
genesis (2). In recent years, there have been important clini-
cal researches on the genes, c-erbB2, p53, Bcl-2, etc., and their
association with breast cancer, including their roles as prog-
nostic or predictive factors (10-16). Bcl-2 has been studied
as a cell survival-promoting protein in a variety of human
tumors with contradictory results. For instance, in accordance
with its anti-apoptotic nature, Bcl-2 has been shown to be
associated with a poorer prognosis in prostate and colon can-
cers, and neuroblastoma (17). In breast cancer, on the other
hand, Bcl-2 expression has been reported to be associated
with better outcomes and improved disease-free survival,
although Bcl-2 was not an independent prognostic variable
(19). Complex interactions among the various Bcl-2 family
members determine the outcome in terms of cell progression
toward either apoptotic cell death or survival (20, 21). The
Bfl-1 gene is one of the Bcl-2 related genes recently identified
by computer analysis of the expressed sequenced tag databas-
es constructed by random cDNA clones from a human fetal
liver (5, 23). The Bfl-1 gene, as a member of the Bcl-2 fami-
ly, was reported to have 72% homology to the murine A1
gene, one of the Bcl-2-related genes. The Bfl-1 gene contains
the BH1 and BH2 domains, which are known to be impor-
tant regulators for apo-ptosis in Bcl-2-related proteins (22).
Recently, some investigators demonstrated that the Bfl-1 is
a direct transcriptional target of NF- B, and thus the activa-
tion of Bfl-1 may be the means by which NF- B‚ promotes
oncogenesis and cell resistance to anticancer therapy. The
expression patterns of other Bcl-2 related genes are very dis-
tinctive (6). The Bfl-1 gene was highly expressed in bone
marrow and was also present in hematopoietic cell lines, such
as Raji and HL60, and in some normal adult tissues includ-
ing the lung, spleen, and esophagus. It was not, however,
detected in the heart, testis, thyroid, or brain (7). Conflict-
ing data have been reported on the Bfl-1 gene expression in
different tumor tissues: a high rate of expression in gastric
(86%) and colon cancer (93%) specimens, a low rate of expres-
sion in breast cancer (33%), bone and soft tissue sarcoma, and
ovarian cancer specimens, and a very low rate in some human
cancer cell lines (7). We performed a study on the Bfl-1 ex-
pression in a series breast cancer samples to analyze and cor-
relate the expression with the clinicopathological features of
the patients and other prognostic factors, including Bcl-2
and tumor infiltrating lymphocytes. The latter is considered
to reflect the host’s effort to resist tumor growth and has
predictive values also (26). In our study, Bfl-1 was expressed
in 36.7% as a mRNA band on sensitive RT-PCR. These data
were in agreement with the previous observation by Park et
al. who demonstrated the Bfl-1 gene was expressed at a low
rate (33.3%) in breast cancer (7). 
There have been reports that the function of Bfl-1 is dis-
tinct from that of Bcl-2 because Bfl-1 permits cell prolifera-
tion by its structural variation (6), while the two molecules
have a similar function, inhibition of apoptosis. Bcl-2 ex-
pression has been reported to be associated with better out-
comes and factors that have favorable prognosis, although
Bcl-2 was not an independent prognostic variable (19). In
the present study, expression of the Bcl-2 protein on immu-
nohistochemistry has a significant association with the hor-
monal receptors and c-erbB2 (data not shown). Indeed, these
patterns were similar to the results for Bfl-1. In the patient
groups with the higher level of Bf1-1 expression intensity,
the tumors were positive for hormonal receptors and nega-
tive for p53 or c-erbB2, which are known as good prognos-
tic markers. A good correlation was found between the ex-
pression of the Bfl-1 gene and the estrogen receptor only.
When the intensities of Bfl-1 gene expression were com-
pared with the characteristics, including existing prognostic
factors, there were no statistically significant parameters.
But considering the trend of higher expression in the cancer
tissues of patients with larger tumors, axillary nodal metas-
tasis, or extranodal tumor ex-tension, this observation sug-
gests that Bfl-1 could possibly play a role in advanced cases
of breast cancer. Interestingly, there were no significant asso-
ciation of the expression of the Bcl-2 protein with the tumor
size or staging as showing a significant difference on the
expression of the Bfl-1 gene. Breast cancer cells are often
surrounded by inflammatory cell infiltrates as a sign of tumor-
host interaction and the presence of lymphocyte infiltratesBfl-1 Gene Expression In Breast Cancer 229
is considered to reflect the host’s effort to resist tumor growth
(26). Some authors have related the presence of tumor infil-
trating lymphocytes to favorable prognosis (27). A study in
gastric carcinoma suggests that inflammatory cells may be
the major source of Bfl-1 gene ex-pression. In a study that
utilized the mRNA in situ hybridization technique, Ha et
al. (8) showed that the signal for Bfl-1 was localized within
the inflammatory cells, including neutrophils and eosinophils.
In the present study, we examined whether the expression
of the Bfl-1 gene has a correlation with the infiltration of
lymphocytes in breast cancer as preliminary research. We
found no association between the expression of Bfl-1 and
the densities of tumor infiltrating lymphocytes, although
further studies are needed before drawing a definite conclu-
sion.
In conclusion, it seems that the increased expression of
the Bfl-1 gene serves as an contributory factor in breast can-
cer, in the same way that another group of genes, the Bcl-2
family, contribute to apoptosis. The Bfl-1 gene was related
to more advanced breast cancer and to factors that have
favorable prognosis. However in order to know if the Bfl-1
gene may be influential in the clinical manifestation mecha-
nism and outcomes of breast cancer, long-term follow-up of
patients with further research on the role of the gene is
needed. 
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